ADCETRIS Drug Insight and Market Forecast - 2032

“ADCETRIS Drug Insight and Market Forecast - 2032” report provides comprehensive insights about ADCETRIS for Cutaneous T-cell lymphoma (CTCL) in the seven major markets. A detailed picture of the ADCETRIS for Cutaneous T-cell lymphoma in the 7MM, i.e., the United States, EU4 (Germany, France, Italy and Spain) and the United Kingdom, and Japan for the study period 2019-2032 is provided in this report along with a detailed description of the ADCETRIS for Cutaneous T-cell lymphoma. The report provides insight about mechanism of action, dosage and administration, as well as research and development activity including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the ADCETRIS market forecast, analysis for Cutaneous T-cell lymphoma in the 7MM descriptive analysis such as SWOT, analyst views, comprehensive overview of market competitors, and brief about other emerging therapies in Cutaneous T-cell lymphoma.

Drug Summary

ADCETRIS (Brentuximab vedotin) targets CD30 using our proprietary antibody-drug conjugate (ADC) technology. CD30 is found on the surface of most classical Hodgkin lymphoma (HL) cells and in several types of non-Hodgkin lymphoma but is not commonly found on healthy cells. This ADC therapy uses a linker system that is designed to be stable in the bloodstream and release a cytotoxic (cell-killing) agent once internalized into CD30-expressing cells, resulting in targeted cell death. Brentuximab vedotin is composed of an anti-CD30 monoclonal antibody and a cytotoxic agent, monomethyl auristatin E (MMAE), which are attached by a protease-cleavable linker.

The prescribing information for ADCETRIS also includes a boxed warning related to the risk that JC virus infection resulting in progressive multifocal leukoencephalopathy and death can occur in patients receiving ADCETRIS. The drug is being developed in collaboration with Takeda Pharmaceutical Company. Beyond the current labeled indications, the company is evaluating ADCETRIS as monotherapy and in combination with other agents in ongoing trials.

ADCETRIS injection for intravenous infusion has received FDA approval for four indications, including regular approval for patients with pcALCL and CD30-expressing MF and who have received prior systemic therapy. CD30 is a member of the tumor necrosis factor receptor family. It is expressed on the surface of sALCL cells and on Hodgkin Reed-Sternberg (HRS) cells in cHL and has limited expression on healthy tissue and cells. In vitro data suggest that signaling through CD30-CD30L binding may affect cell survival and proliferation. Brentuximab vedotin is an ADC. The antibody is a chimeric IgG1 directed against CD30. The small molecule, MMAE, is a microtubule-disrupting agent, and MMAE is covalently attached to the antibody via a linker. Nonclinical data suggest that the anticancer activity of ADCETRIS is due to the binding of the ADC to CD30-expressing cells, followed by internalization of the ADC-CD30 complex and the release of MMAE via proteolytic cleavage. The binding of MMAE to tubulin disrupts the microtubule network within the cell, causing cell cycle arrest and apoptotic death of the cells. Additionally, in vitro data prove antibody-dependent cellular phagocytosis (ADCP).

Scope of the Report

The report provides insights into:

• A comprehensive product overview including the ADCETRIS description, mechanism of action, dosage and administration, research and development activities in Cutaneous T-cell lymphoma.
• Elaborated details on ADCETRIS regulatory milestones and other development activities have been provided in this report.
• The report also highlights the ADCETRIS research and development activity in Cutaneous T-cell lymphoma in detail across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around ADCETRIS.
• The report contains forecasted sales of ADCETRIS for Cutaneous T-cell lymphoma till 2032.
• Comprehensive coverage of the late-stage emerging therapies for Cutaneous T-cell lymphoma.
• The report also features the SWOT analysis with analyst views for ADCETRIS in Cutaneous T-cell lymphoma.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by the research team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

ADCETRIS Analytical Perspective

In-depth ADCETRIS Market Assessment

This report provides a detailed market assessment of ADCETRIS in Cutaneous T-cell lymphoma in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2023 to 2032.

ADCETRIS Clinical Assessment

The report provides the clinical trials information of ADCETRIS in Cutaneous T-cell lymphoma covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights

• In the coming years, the market scenario for Cutaneous T-cell lymphoma is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.

The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence ADCETRIS dominance.

• Other emerging products for Cutaneous T-cell lymphoma are expected to give tough market competition to ADCETRIS and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of ADCETRIS in Cutaneous T-cell lymphoma.
• The in-depth analysis of the forecasted sales data from 2023 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the ADCETRIS in Cutaneous T-cell lymphoma.

Key Questions Answered

• What is the product type, route of administration and mechanism of action of ADCETRIS?
• What is the clinical trial status of the study related to ADCETRIS in Cutaneous T-cell lymphoma and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the ADCETRIS development?
• What are the key designations that have been granted to ADCETRIS for Cutaneous T-cell lymphoma?
• What is the forecasted market scenario of ADCETRIS for Cutaneous T-cell lymphoma?
• What are the forecasted sales of ADCETRIS in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available in Cutaneous T-cell lymphoma and how are they giving competition to ADCETRIS for Cutaneous T-cell lymphoma?
• Which are the late-stage emerging therapies under development for the treatment of Cutaneous T-cell lymphoma?

This product will be delivered within 2 business days.